Laux G, Classen W, Sofic E, Becker T, Riederer P, Lesch K P, Struck M, Beckmann H
Department of Psychiatry, University of Würzburg, Federal Republic of Germany.
J Neural Transm Suppl. 1990;32:189-95. doi: 10.1007/978-3-7091-9113-2_28.
N = 53 inpatients with major depressive disorder have been treated with the reversible, selective MAO-A-inhibitors moclobemide (double-blind versus maprotiline) and brofaromine (open study), respectively. Clinically, significant improvement of depression and an activating profile of action could be observed, typical side effects were sleep disturbances, agitation and weight loss. The neurobiochemical data showed an increase of noradrenaline plasma concentrations under treatment with moclobemide. Visual reaction times improved with antidepressant treatment. MAO-A inhibitors proved to be effective antidepressants in the treatment of hospitalized patients with predominantly endogenous depressions.
53例重度抑郁症住院患者分别接受了可逆性、选择性单胺氧化酶-A抑制剂吗氯贝胺（与麦普替林双盲对照）和溴法罗明（开放性研究）治疗。临床上，可观察到抑郁症状显著改善以及具有激活作用的行为表现，典型的副作用为睡眠障碍、激越和体重减轻。神经生化数据显示，接受吗氯贝胺治疗的患者血浆去甲肾上腺素浓度升高。抗抑郁治疗后视觉反应时间有所改善。单胺氧化酶-A抑制剂被证明是治疗以内源性抑郁为主的住院患者的有效抗抑郁药。
